<SEC-DOCUMENT>0001193125-21-200549.txt : 20210812
<SEC-HEADER>0001193125-21-200549.hdr.sgml : 20210812
<ACCEPTANCE-DATETIME>20210625170602
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-21-200549
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210625

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Erasca, Inc.
		CENTRAL INDEX KEY:			0001761918
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831217027
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		10835 ROAD TO THE CURE, SUITE 140
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 465-6511

	MAIL ADDRESS:	
		STREET 1:		10835 ROAD TO THE CURE, SUITE 140
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12670 High Bluff Drive</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego,
California 92130</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel:&nbsp;+1.858.523.5400&nbsp;Fax:&nbsp;+1.858.523.5450</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">www.lw.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g166198g59e25.jpg" ALT="LOGO">
</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 25, 2021</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>VIA EDGAR</U></B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Tonya&nbsp;K. Aldave</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Life Sciences</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street N.E.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">FIRM&nbsp;/AFFILIATE&nbsp;OFFICES</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beijing</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brussels</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Century City</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chicago</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dubai</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">D&uuml;sseldorf</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frankfurt</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hamburg</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hong Kong</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Houston</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Los Angeles</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Milan</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moscow</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Munich</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orange County</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paris</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Riyadh</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seoul</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shanghai</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Silicon Valley</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Singapore</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tokyo</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Erasca, Inc. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Amendment No.&nbsp;1 to Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Submitted June&nbsp;9, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>CIK No.&nbsp;0001761918 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear
Ms.&nbsp;Aldave: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are in receipt of the Staff&#146;s letter dated June&nbsp;21, 2021 with respect to the above-referenced confidential
Amendment No.&nbsp;1 to the draft Registration Statement (the &#147;<B><I>DRS</I></B>&#148;). We are responding to the Staff&#146;s comments on behalf of Erasca, Inc. (&#147;<B><I>Erasca</I></B>&#148; or the &#147;<B><I>Company</I></B>&#148;) as set
forth below. Simultaneously with the submission of this letter, the Company is publicly filing via EDGAR a revised Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;<B><I>Registration Statement</I></B>&#148;)
responding to the Staff&#146;s comments and updating the DRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s responses set forth in this letter are numbered to
correspond to the numbered comments in the Staff&#146;s letter. All terms used but not defined herein have the meanings assigned to such terms in the Registration Statement. For ease of reference, we have set forth the Staff&#146;s comments and the
Company&#146;s response for each item below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Prospectus summary, page 1 </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your response to our prior comment 4 and reissue. For each of the nine programs in the discovery and
the <FONT STYLE="white-space:nowrap">IND-enabling</FONT> stages, please provide us with a detailed analysis of why each of those programs is sufficiently material to your business to warrant inclusion in your pipeline table or revise your table to
remove programs that are not sufficiently material. In this regard we note, as examples only, that you do not list the programs currently in discovery or in the <FONT STYLE="white-space:nowrap">IND-enabling</FONT> stage on your website, you do not
appear to discuss them in your Management&#146;s Discussion and Analysis of Financial Condition section, and you do not appear to have plans to use the proceeds of this offering to advance all of these programs. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Erasca&#146;s Response: In light of the Staff&#146;s comment, the Company has reconsidered the materiality of each of the discovery and <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> stage programs described in the pipeline table. After careful consideration, the Company has removed two of the discovery programs from the table: <FONT STYLE="white-space:nowrap">ERAS-9</FONT> and <FONT
STYLE="white-space:nowrap">ERAS-11.</FONT> However, the Company strongly believes that the remaining seven programs are material to its </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>June 25, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 2
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g166198g59e25.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development strategy and essential to an understanding of the investment opportunity and has provided a detailed analysis below. In addition, the Company advises the Staff that the Company is in
the process of updating its website to conform to the disclosure in the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As background before addressing each
program individually, Erasca would like to remind the Staff that since the Company&#146;s founding, Erasca has focused on discovering and developing new product candidates based on differentiated approaches to shut down <FONT
STYLE="white-space:nowrap">RAS-driven</FONT> cancers. The Company realized early on that RAS may evade direct inhibition via multiple mechanisms&#151;both <FONT STYLE="white-space:nowrap">in-pathway</FONT> and beyond. To combat this, the Company has
internally developed its own research programs, which have been complemented by a parallel corporate development strategy to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire assets with the goal of comprehensively shutting down the
RAS/MAPK pathway with single agents and rational combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As indicated in the Registration Statement, the Company&#146;s efforts are
rooted in a deep understanding of the biology of the RAS/MAPK pathway and are focused on finding the right molecules in a modality-agnostic manner rather than relying on a single, platform-specific approach. The Company&#146;s development programs
have been designed to allow it to target not just individual signaling nodes in the RAS/MAPK pathway, but multiple nodes and cooperative mechanisms in concert. As described further below, the Company&#146;s strategy is focused on targeting multiple
nodes and cooperative mechanisms of the RAS/MAPK pathway in parallel, rather than targeting a single node. When viewed in totality, the development programs that the Company presents in the pipeline table target every critical node in the RAS/MAPK
pathway, which the Company believes is essential to a prospective investor&#146;s understanding of the Company&#146;s strategy, capabilities and development efforts <FONT STYLE="white-space:nowrap">to-date.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company addresses below each of the seven discovery and <FONT STYLE="white-space:nowrap">IND-enabling</FONT> stage programs included in
the pipeline table of the Registration Statement with specificity so the Staff will have the benefit of the Company&#146;s detailed analysis:&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ERAS-801</FONT></B> &#150; Approved EGFR inhibitors do not effectively target primary brain tumors
(<I>e.g.</I>, glioblastoma multiforme (&#147;<B><I>GBM</I></B>&#148;)). The Company believes this is because of (1)&nbsp;the molecules&#146; inability to adequately penetrate the central nervous system (&#147;<B><I>CNS</I></B>&#148;) and
(2)&nbsp;the molecules being weak inhibitors of EGFR mutations observed in GBM, which are distinct from EGFR mutations observed in <FONT STYLE="white-space:nowrap">non-small</FONT> lung cancer. As described in the Registration Statement, <FONT
STYLE="white-space:nowrap">ERAS-801</FONT> was specifically designed to address these key limitations, including having enhanced CNS penetration (~4x greater penetration than approved EGFR inhibitors) and the ability to target clinically relevant
EGFR alterations in GBM, such as EGFR amplification and EGFRvIII mutations. The Company entered into an exclusive worldwide license agreement in 2020 with Katmai Pharmaceuticals for this program, and the license agreement is described in the
Registration Statement (&#147;<I>Business&#151;Our acquisition and license agreements&#151;Katmai Pharmaceuticals</I>&#148; as well as throughout MD&amp;A) and filed as a material agreement (Exhibit 10.17). The Company anticipates filing an IND in
the first quarter of 2022, as disclosed in the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ERAS-1</FONT> </B>&#150; The
historic discovery by Dr.&nbsp;Kevan Shokat, one of the Company&#146;s <FONT STYLE="white-space:nowrap">co-founders,</FONT> of the switch II pocket <FONT STYLE="white-space:nowrap">(S-IIP)</FONT> has spurred the development of multiple KRAS G12C
inhibitors, including one from Amgen that recently received FDA approval. However, current inhibitors of which the Company is aware do not adequately address the propensity for certain tumors (<I>e.g.</I>,
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer) to metastasize to the brain. The Company specifically designed and optimized the <FONT STYLE="white-space:nowrap">ERAS-1</FONT> program to have comparable or superior activity as
compared to other KRAS G12C inhibitors in development plus a robust ability to cross the blood-brain barrier (&#147;<B><I>BBB</I></B>&#148;) in order to address this key limitation of other KRAS G12C inhibitors. The Company believes its <FONT
STYLE="white-space:nowrap">ERAS-1</FONT> <FONT STYLE="white-space:nowrap">pre-candidates</FONT> are the only KRAS G12C inhibitors specifically designed to cross the BBB and have the potential to be the only candidates to be able to do so. The
Company expects to nominate a development candidate (&#147;<B><I>DevCan</I></B>&#148;) from one of its <FONT STYLE="white-space:nowrap">pre-candidates</FONT> in the second half of 2021 and file an IND in the second half of 2022. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>June 25, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 3
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g166198g59e25.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ERAS-2/3</FONT></B> &#150; Targeting <FONT
STYLE="white-space:nowrap">non-G12C</FONT> RAS mutations (the focus of the Company&#146;s <FONT STYLE="white-space:nowrap">RAS-GTP</FONT> franchise, including <FONT STYLE="white-space:nowrap">ERAS-4</FONT> and
<FONT STYLE="white-space:nowrap">ERAS-2/3)</FONT> is more challenging than targeting KRAS G12C. Dr.&nbsp;Shokat, who is a professor at UCSF, identified a novel region on RAS called the switch II groove
<FONT STYLE="white-space:nowrap">(S-IIG),</FONT> which is present in the <FONT STYLE="white-space:nowrap">RAS-GTP</FONT> state. This novel finding and the associated 2018 exclusive worldwide license agreement with UCSF for Dr.&nbsp;Shokat&#146;s
work related to <FONT STYLE="white-space:nowrap">RAS-GTP</FONT> were the foundation for forming the Company and for Dr.&nbsp;Shokat being a <FONT STYLE="white-space:nowrap">co-founder</FONT> of the Company. No
<FONT STYLE="white-space:nowrap">RAS-GTP</FONT> inhibitor has been approved to date, so the Company believes this program is material to disclose to investors based on its potential groundbreaking nature. The license agreement with UCSF is described
in the Registration Statement (&#147;<I>Business&#151;Our acquisition and license agreements&#151;University of California, San Francisco&#148;</I>) and filed as a material agreement (Exhibit 10.15). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ERAS-4</FONT></B> &#150; The focus of the <FONT STYLE="white-space:nowrap">ERAS-4</FONT> program is
developing small molecules that potently and selectively bind to KRAS G12D. This mutation, which is even more common than KRAS G12C, is difficult to target for several reasons described in the Registration Statement, including that <FONT
STYLE="white-space:nowrap">non-G12C</FONT> mutations do not have a mutant-specific site for irreversible inhibitor binding. As such, there are very few companies of which the Company is aware that have been able to discover tractable starting points
and none of which the Company is aware that have entered clinical trials. Therefore, the Company believes that its recent breakthrough of potent and selective compounds (described in the Registration Statement (in particular,
&#147;<I>Business&#151;Our <FONT STYLE="white-space:nowrap">pipeline&#151;ERAS-4:</FONT> our KRAS G12D program</I>&#148;)), positions the Company favorably relative to other companies in this space to be able to nominate and advance a DevCan that
could become a meaningful therapy for patients with tumors driven by this mutation. MAPKlamp combinations involving KRAS G12D inhibitors support the Company&#146;s strategy of targeting colorectal cancer and pancreatic ductal adenocarcinoma since
the G12D mutation is the most frequent KRAS mutation observed in both cancer types. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ERAS-5</FONT></B>
&#150; Autophagy is a key escape route mechanism in tumor cells where RAS/MAPK pathway signaling is inhibited. The ULK1 and ULK2 kinases are key regulators of autophagy. Thus, developing inhibitor(s) of these kinases is a key aspect of targeting
escape routes (the Company&#146;s third therapeutic strategy). The Company entered into an exclusive worldwide license agreement in 2020 with LifeArc for this program, and the license agreement is described in the Registration Statement
(&#147;<I>Business&#151;Our acquisition and license agreements&#151;LifeArc&#148;</I>)<I> </I>and filed as a material agreement (Exhibit 10.18). The Company has identified a promising <FONT STYLE="white-space:nowrap">ERAS-5</FONT> compound that
showed strong potency, target engagement, inhibition of autophagy, and selectivity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ERAS-10</FONT></B> &#150; The Company&#146;s modality-agnostic approach aims to allow the Company to
selectively and potently inhibit or degrade critical signaling nodes with small molecule therapeutics, large molecule therapeutics, and protein degraders. A key differentiator of the Company&#146;s strategy has been to assemble a robust pipeline,
irrespective of modality &#150; this is a material aspect of the Company&#146;s strategy to disclose to investors. The Company&#146;s goal has been to start with the biology of the RAS/MAPK pathway and then find the best modality and asset to shut
it down, alone and in combination. <FONT STYLE="white-space:nowrap">ERAS-10,</FONT> the Company&#146;s protein degrader program, is thus an important component of the Company&#146;s modality-agnostic strategy, and the Company has strong <FONT
STYLE="white-space:nowrap">in-house</FONT> capabilities and expertise with its development team in this area. As the main component of its protein degrader strategy, the Company strongly believes this program represents a material part of its
development strategy and pipeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ERAS-12</FONT></B> &#150; All approved anti-EGFR antibodies target
domain III (D3) only, which is accessible for antibody binding only in the inactive conformation of wildtype EGFR, and no approved antibodies </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>June 25, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 4
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g166198g59e25.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
target domain II (D2), which is accessible for antibody binding only in the active, ligand-bound conformation of wildtype EGFR. Antibodies targeting D2 are expected to be more effective when
epidermal growth factor (EGF) or other members of the EGF family are overexpressed. The Company is developing a bispecific antibody that is active against both the inactive and active conformations of wildtype EGFR, and the Company anticipates
filing an IND for this program by 2024. Achieving a higher level of EGFR inhibition may better control tumor growth and delay the emergence of resistance mechanisms that drive EGFR into the active conformation, thereby addressing a key limitation of
approved anti-EGFR antibodies. The Company acquired this program in 2021 from Emerge Life Sciences, and the asset purchase agreement is described in the Registration Statement (&#147;<I>Business&#151;Our acquisition and license
agreements&#151;Emerge LifeSciences&#148;</I>) and filed as a material agreement (Exhibit 10.21). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing, coupled with
the existing disclosure in the Registration Statement (including the filing of acquisition/license agreements for the applicable programs as material agreement exhibits and the separate bullet in &#147;Use of Proceeds&#148; setting forth expected
proceeds to be used for the discovery and <FONT STYLE="white-space:nowrap">pre-IND</FONT> stage programs), the Company strongly believes that each of the foregoing programs is sufficiently material to its business to warrant inclusion in the
pipeline. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Refer to your response to our prior comment 5. Your pipeline table, which indicates that you are currently
in Phase 1 of <FONT STYLE="white-space:nowrap">HERKULES-2,</FONT> <FONT STYLE="white-space:nowrap">HERKULES-3</FONT> and <FONT STYLE="white-space:nowrap">HERKULES-4</FONT> clinical trials, appears to be inconsistent with your disclosure on pages 4
and 127 that you are planning to begin the dosing of first patients in <FONT STYLE="white-space:nowrap">HERKULES-2,</FONT> <FONT STYLE="white-space:nowrap">HERKULES-3,</FONT> and <FONT STYLE="white-space:nowrap">HERKULES-4</FONT> in the future. If
these trials have not yet begun, please revise your pipeline table here and throughout the registration statement accordingly. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Erasca&#146;s Response: The Company has revised the pipeline table on pages 4, 110 and 125 of the Registration Statement in response to the
Staff&#146;s comment, to clarify that the <FONT STYLE="white-space:nowrap">HERKULES-2,</FONT> <FONT STYLE="white-space:nowrap">HERKULES-3,</FONT> and <FONT STYLE="white-space:nowrap">HERKULES-4</FONT> trials are planned and that the <FONT
STYLE="white-space:nowrap">HERKULES-1</FONT> trial is ongoing. In addition, the Company has updated the pipeline table to indicate that a Phase 1 trial for <FONT STYLE="white-space:nowrap">ERAS-007</FONT> was previously completed by Asana, to
further clarify why the applicable rows of the pipeline table for <FONT STYLE="white-space:nowrap">ERAS-007</FONT> are shown in the Phase 1 stage, while acknowledging that for such rows the relevant HERKULES trials have not yet commenced. The
Company respectfully advises the Staff that this presentation is consistent with the disclosure throughout the Registration Statement that the dosing of such HERKULES trials is expected on the timelines indicated therein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Business </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Patient lives at stake annually
with RAS/MAPK pathway alterations, page 120 </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>3.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please provide support for your statement here as it relates to your belief that &#147;[y]our deep and
focused pipeline has the potential to target 100% of CRC, ~90% of pancreatic cancer, ~70% of head and neck squamous cell carcinoma (HNSCC), ~65% of melanoma, ~55% of GBM, ~40% of NSCLC, and ~40% of AML, and also the potential to provide targeted
therapy options for many patients with RAS/MAPK pathway-driven tumors in a wide range of less common histologies.&#148; In this regard, we note that you appear to have only one product candidate in Phase 1 and one product candidate in Phase 2 of
clinical trials and that all remaining product candidates are still either in discovery or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> trials. In addition, none of the types of cancers you reference in this statement appear to be included
as specific indications in your pipeline table. </I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Erasca&#146;s Response: The Company has removed the statement on
page 120 of the Registration Statement in response to the Staff&#146;s comment. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>June 25, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 5
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g166198g59e25.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U><FONT STYLE="white-space:nowrap">ERAS-601:</FONT> our SHP2 inhibitor, page 147 </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>4.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your response to our prior comment 11 and reissue in part. Please identify the four serious adverse
events (SAEs) observed in the clinical trial referenced on pages 152 and 153. </I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has revised the
disclosure on page 154 of the Registration Statement in response to the Staff&#146;s comment to identify the four serious adverse events. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Our
acquisition and license agreements </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>University of California, San Francisco, page 176 </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>5.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your response to our prior comment 13 and reissue in part. On page 177, you state that you are
obligated to pay tiered sublicensing fees ranging from &#147;low double digit percentages to up to 30%.&#148; Please revise to clarify what you mean by &#147;low double digit percentages&#148; so that investors understand the potential range of
royalty payments in a range not to exceed ten percent. If the range is more than ten percent, please provide a range within ten percent for each tier or disclose the number of tiers. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Erasca&#146;s Response: The Company has revised the disclosure on page 177 of the Registration Statement in response to the Staff&#146;s
comment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Government Regulation </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Foreign
Regulation, page 191 </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>6.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your response to our prior comment 12 and reissue. Please revise this section to describe the
approval process in China and Japan. </I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Erasca&#146;s Response: The Company has revised the disclosure starting on
page 198 of the Registration Statement in response to the Staff&#146;s comment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">********* </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any comments or questions regarding the foregoing should be directed to the undersigned at (858)
<FONT STYLE="white-space:nowrap">523-3962.</FONT> Thank you in advance for your cooperation in connection with this matter. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Matthew T. Bush</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew T. Bush</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">of LATHAM&nbsp;&amp; WATKINS
LLP</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sonia Bednarowski, <I>Securities and Exchange Commission</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Angela Connell,&nbsp;<I>Securities and Exchange Commission</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Julie Sherman, <I>Securities and Exchange Commission</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Jonathan Lim, M.D.,&nbsp;<I>Erasca, Inc.</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">David M. Chacko, M.D., <I>Erasca, Inc.</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Ebun Garner, <I>Erasca, Inc.</I> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>June 25, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 6
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g166198g59e25.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Cheston Larson,&nbsp;<I>Latham&nbsp;&amp; Watkins LLP</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Charles Kim, <I>Cooley LLP</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Sean Clayton, <I>Cooley LLP</I> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g166198g59e25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g166198g59e25.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M 8H 6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
1"@ H * "@ H * "@ H __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
